Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$12.9 - $18.88 $64,500 - $94,400
5,000 Added 30.86%
21,201 $287,000
Q2 2023

Aug 09, 2023

SELL
$15.63 - $22.01 $37,512 - $52,824
-2,400 Reduced 12.9%
16,201 $277,000
Q1 2023

May 10, 2023

SELL
$19.17 - $27.7 $40,257 - $58,170
-2,100 Reduced 10.14%
18,601 $375,000
Q4 2022

Feb 08, 2023

BUY
$15.92 - $30.52 $329,559 - $631,794
20,701 New
20,701 $606,000

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $60.1M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.